Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$364.75 0.00 (0.00)%

High N/A Low N/A Volume N/A Market Cap 38.65B
07/16/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Jul 09

    Regeneron to Report Second Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on August 2, 2018

    Read on
  • Jun 06

    Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health

    Read on

EVENTS

  • Regeneron Pharmaceuticals Q2 2018 Earnings Conference Call
    Aug 2, 2018

Events & Presentations

NASDAQ REGN

$364.75 0.00 (0.00)%

High N/A Low N/A Volume N/A Market Cap 38.65B
07/16/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information